Spinal Cord Injury: Long-Term Medication Management on a Pharmacy Lien

James Wong — Founder & Pharmacist, LienScripts | November 19, 2025 | 7 min read

Spinal cord injuries produce the most complex and long-duration medication needs of any personal injury case type. Learn which medications SCI patients require — from neuropathic pain and spasticity management to neurogenic bladder, bowel, and mood — and how a pharmacy lien documents this record throughout the case.

Spinal Cord Injury: Long-Term Medication Management on a Pharmacy Lien

Spinal cord injury (SCI) stands apart from every other injury type in personal injury law — not only in the severity of its consequences but in the duration and complexity of the medical management it requires. Whether the injury results in paraplegia, quadriplegia, or an incomplete SCI with partial motor and sensory function preserved, the pharmaceutical needs of an SCI patient are multisystem, lifelong, and begin from the day of injury.

For attorneys handling SCI cases, understanding the full scope of the medication profile is essential to accurately assessing damages — and to ensuring the client's treatment is fully documented from the earliest stages of the case.

[!KEY] Spinal cord injury requires simultaneous pharmaceutical management of neuropathic pain, spasticity, neurogenic bladder, neurogenic bowel, and mood — the multi-system medication record is among the most powerful exhibits in documenting the real and ongoing consequences of the injury.

Complete vs. Incomplete Spinal Cord Injury

Spinal cord injuries are classified using the American Spinal Injury Association (ASIA) Impairment Scale:

• Complete SCI (ASIA A) — no motor or sensory function preserved below the level of injury
• Incomplete SCI (ASIA B through D) — partial preservation of sensory and/or motor function below the injury level

Incomplete SCIs are actually more common than complete injuries and carry their own complex medication profiles. Both complete and incomplete SCIs require extensive, long-duration pharmaceutical management across multiple organ systems.

The level of injury — cervical, thoracic, or lumbar — determines which body systems are affected and which medications are required. Cervical SCI affecting the upper extremities and respiratory function creates a broader medication burden than a lower lumbar injury with preserved upper extremity and pulmonary function.

Neuropathic Pain: The Central Medication Challenge

Neuropathic pain is present in the majority of SCI patients and is often described as the most disabling non-motor consequence of spinal cord injury. It is characterized by burning, stabbing, electric, or aching pain at and below the level of injury — pain that arises from disordered signaling in the injured and reorganizing nervous system rather than from tissue damage in the traditional sense.

Standard analgesics — NSAIDs and even opioids — provide incomplete relief for SCI neuropathic pain. The primary pharmacological targets are medications that modulate abnormal neural signaling.

First-Line Neuropathic Agents

• Gabapentin (Neurontin) — the most commonly prescribed medication for SCI-related neuropathic pain. Dosing in SCI is often substantially higher than in other neuropathic pain conditions — many SCI patients require 1800mg to 3600mg per day (in divided doses) to achieve adequate pain control. The medication must be titrated gradually to this level, typically over several weeks
• Pregabalin (Lyrica) — a structural analog of gabapentin with a more linear pharmacokinetic profile and potentially faster titration. Also used at higher doses in SCI — 300mg to 600mg per day — and is FDA-approved for central neuropathic pain

Second-Line and Adjunct Neuropathic Agents

• Duloxetine (Cymbalta) — an SNRI with demonstrated efficacy in multiple neuropathic pain conditions; often added when gabapentin or pregabalin alone provides insufficient relief
• Amitriptyline — a tricyclic antidepressant used at lower doses (25mg to 100mg at bedtime) for neuropathic pain; also provides benefit for sleep and mood
• Tramadol — a weak opioid with additional norepinephrine-serotonin reuptake inhibition properties; used as an adjunct for SCI pain when other agents are insufficient

Spasticity: A Near-Universal Consequence of Upper Motor Neuron SCI

Spasticity — increased muscle tone and involuntary muscle spasm — occurs in the majority of patients with cervical or thoracic SCI due to disruption of upper motor neuron pathways. Spasticity can cause pain, interfere with positioning, complicate transfers and mobility, and significantly impair quality of life. It can also cause joint contractures if not managed adequately.

Antispasticity Medications

• Baclofen (Lioresal) — the primary antispasticity agent for SCI. SCI patients often require substantially higher doses than those used in non-SCI spasticity conditions — daily doses of 60mg to 120mg (in divided doses) are common, compared to 10-30mg in less severe conditions. In patients whose spasticity is not adequately controlled with oral baclofen, intrathecal baclofen (ITB) delivered via implanted pump may be considered — a significant surgical and pharmaceutical undertaking
• Tizanidine (Zanaflex) — a central alpha-2 agonist that reduces spasticity through a different mechanism than baclofen; often used in combination with or as an alternative to baclofen. Dosing ranges from 4mg to 36mg per day
• Dantrolene sodium (Dantrium) — acts directly on muscle rather than the central nervous system; used in severe spasticity cases, particularly when central side effects of baclofen or tizanidine are limiting; requires liver function monitoring with long-term use
• Diazepam or clonazepam — benzodiazepines used as adjuncts for severe or refractory spasticity, typically in low doses to avoid excessive sedation

Neurogenic Bladder: A Universal Management Challenge

Neurogenic bladder — loss of voluntary control of bladder function due to spinal cord injury — is present in virtually all patients with SCI above the sacral segments. Left unmanaged, neurogenic bladder creates risk of urinary tract infections, kidney damage, and serious quality-of-life impairment. Bladder management is among the most pharmaceutically intensive aspects of SCI care.

Bladder Medications

• Oxybutynin (Ditropan) — an anticholinergic agent that reduces detrusor (bladder muscle) overactivity; the most widely used oral bladder medication in SCI. Extended-release formulations improve tolerability
• Tolterodine (Detrol) — another anticholinergic with a similar mechanism to oxybutynin, often preferred for patients who experience more tolerable side effects
• Mirabegron (Myrbetriq) — a beta-3 adrenergic agonist that relaxes the detrusor muscle through a non-anticholinergic mechanism; useful for patients who cannot tolerate anticholinergic side effects
• Tamsulosin (Flomax) or alfuzosin — alpha-blockers that reduce urethral sphincter resistance; used in male SCI patients and in patients performing intermittent catheterization who experience difficulty with catheter passage
• Solifenacin (VESIcare) or trospium — additional anticholinergic options used when oxybutynin or tolterodine are not well tolerated

Bladder medications in SCI are not short-term prescriptions — they are lifelong medications whose cost and documentation must be fully accounted for in both the pre-settlement pharmacy lien and the post-settlement life care plan.

[!KEY] The neurogenic bladder and bowel medications in the SCI pharmacy record — which are permanent daily prescriptions, not injury-phase medications — are among the most powerful life care plan cost anchors: each monthly fill documents a recurring, lifelong expense that the SCI has imposed on the plaintiff and that the life care plan projects forward.

Neurogenic Bowel Management

SCI disrupts the neural pathways controlling bowel function, resulting in neurogenic bowel — loss of voluntary rectal control, altered colonic motility, and difficulty with defecation. Bowel management is a daily routine for SCI patients and requires consistent pharmaceutical support.

• Stimulant laxatives — bisacodyl (Dulcolax) suppositories or oral tablets and senna are the most commonly used agents; bisacodyl suppositories are used as part of scheduled bowel programs
• Docusate sodium (Colace) — a stool softener used to prevent impaction and ease stool passage
• Polyethylene glycol (MiraLax) — an osmotic laxative used for more refractory constipation
• Glycerin suppositories — used as a reflex-trigger for scheduled bowel programs in lower-level SCI patients

Like bladder medications, bowel management agents are lifelong prescriptions.

DVT Prophylaxis in the Acute Phase

In the days to weeks following SCI, patients face significantly elevated risk of deep vein thrombosis (DVT) due to paralysis and immobility. Anticoagulation therapy is standard of care:

• Enoxaparin (Lovenox) — low molecular weight heparin administered by injection; the most commonly used agent in the acute SCI phase
• Rivaroxaban (Xarelto) or apixaban (Eliquis) — oral anticoagulants that may be transitioned to during the subacute phase based on clinical stability

DVT prophylaxis is typically continued for 3 months following SCI, though clinical judgment guides duration.

Mood, Sleep, and Psychological Medications

Depression following spinal cord injury is documented at rates significantly higher than in the general population. The combination of functional loss, chronic pain, disrupted social role, and uncertain future creates a high psychological burden that warrants proactive pharmaceutical management.

• SSRIs — sertraline (Zoloft), fluoxetine (Prozac), and escitalopram (Lexapro) are commonly prescribed for SCI-related depression; SSRIs with serotonin-norepinephrine activity may provide concomitant pain benefit
• SNRIs — duloxetine (Cymbalta) is particularly useful in SCI because it addresses both depression and neuropathic pain
• Trazodone — a non-addictive sleep agent commonly used in SCI patients with pain-related and medication-related sleep disruption
• Mirtazapine — a sedating antidepressant that simultaneously addresses depression, sleep, and appetite suppression common in SCI

Why the Pharmacy Lien Record Matters in SCI Cases

SCI cases typically resolve over a long timeline — often 2 to 4 years from injury to settlement. During that entire period, a pharmacy lien enrolled at the outset of the case provides:

1. Uninterrupted prescription access — the patient fills every medication as prescribed without gaps caused by inability to pay
2. A complete, continuously updated medication record — every fill date, drug, dose, and quantity is documented
3. Powerful evidence of the ongoing injury burden — a 3-year pharmacy record showing high-dose gabapentin, baclofen, oxybutynin, bladder agents, antidepressants, and sleep medications tells an undeniable story about what the SCI has done to this person's life

[!NOTE] The pharmacy lien record covers the pre-settlement period only — post-settlement pharmaceutical costs in SCI cases are addressed through the life care plan, which projects the established treatment pattern forward across the patient's remaining life expectancy, and the two documents work together to present a complete damages picture.

It is important to understand that the pharmacy lien covers the pre-settlement period only. Post-settlement medication needs — which are lifelong in SCI — are addressed through the life care plan, which projects future pharmaceutical costs for inclusion in the damages model. These two documents work together: the pharmacy lien record establishes the historical treatment pattern; the life care plan projects that pattern forward across the patient's remaining life expectancy.

A well-documented pharmacy lien record from the early stages of an SCI case can be one of the most compelling exhibits in demonstrating the real and ongoing consequences of the injury.

[!KEY] Enrolling an SCI patient in pharmacy lien from the first days after injury — before the clinical picture has fully declared itself — ensures that the complete multi-system medication record is captured from the earliest point, which is far more compelling at trial than records beginning weeks or months into treatment.

If you are an attorney handling an SCI case, visit our attorney resources page to learn more about enrolling your client in a pharmacy lien and how LienScripts supports the long documentation timelines these cases require.

Related Resources

• Attorney Resources
• Specialty Medications in Personal Injury Cases
• Baclofen for Spinal Injury Spasticity
• Pregabalin for Nerve Damage
• Pharmacy Services for Personal Injury Clients: How It Works
• Gabapentin for Personal Injury Cases: What Attorneys Need to Know